Aging isn't wear and tear. It's a missed pickup.
Every day your body builds and demolishes roughly a hundred billion white blood cells — a demolition-and-clearance job bigger than most cities. When the clearance crew is on time, you stay young. When it misses the pickups, you age: the spent cells pile up, turn toxic, and inflame every organ they touch. This summer, three heavyweight papers in Science, Nature and Cell Reports converged on the same heretical idea from three directions. Aging is not your organs wearing out. It is an immune-system housekeeping failure — and it appears to have a single switch, a receptor called EP2, that decides whether the crew keeps working. In mice, turning that switch off kept old organs young. In humans, the longest-lived people on Earth look like the ones whose cellular killing crews never clocked off at all.
A hundred billion pickups a day
Start with the garbage. Neutrophils are the most abundant white blood cells you own — first responders that patrol for bacteria, fungi and viruses, and that sometimes die fighting, spilling web-like traps around invaders. They are also spectacularly short-lived: a neutrophil is lucky to see twelve hours. Roughly ninety percent of them end their shift in the liver, spleen and bone marrow, where other cells quietly dispose of them. The scale is almost absurd — about a hundred billion a day, every day, for decades.
That disposal is not a detail. In aging bodies, most neutrophils that never meet a pathogen slip into senescence — a dysfunctional, half-dead state in which they leak chemicals that damage nearby tissue and stoke inflammation. The older you are, the more of them there are. "Senescent neutrophils are killing our tissues," says Katrin Andreasson, the Stanford neurologist who led the new work. "Clearance of these cells is essential for preventing chronic inflammation."
The crew that does the clearing are tissue-resident macrophages — long-lived cells that settle into each organ before you are born and stay there for life, eating dead and defunct cells on site. "They're the body's garbage collection crew," Andreasson says. "A lot of that garbage is defunct cells." The mechanism the Stanford group describes is a creeping deafness: with age, levels of the inflammatory hormone PGE2 rise, and so does the density of its receptor EP2 on resident macrophages. Chronic stimulation of EP2 weakens the macrophages' ability to swallow spent neutrophils. The crew is still there, still on the clock — it just stops hearing the calls. The garbage accumulates; the organs pay.
One receptor, eight organs
The clean way to test that idea is to remove the switch. Andreasson's lab engineered mice in which EP2 could be deleted at will — and deleted it only in tissue-resident macrophages, when the mice were four to six months old, their "teenage" years. Then they waited for old age: 23 to 25 months, roughly a human 60s or 70s. What they found is the kind of result that makes grant reviewers suspicious.
Old mice without EP2 on their resident macrophages retained younger phenotypes across the brain, heart, skeletal muscle, liver, spleen, bone marrow, kidney and colon. They were leaner, with less visceral fat and more muscle. They matched young mice on speed, balance and forelimb grip strength. They navigated mazes and recognised objects almost as well as youngsters — while out-performing same-age controls whose EP2 receptors were still firing. Inflammation markers were down in the blood, liver, colon, heart, kidney and the hippocampus, the brain's memory hub.
And the effect shows up in the blood. The team identified 71 blood proteins whose levels had drifted significantly in normal old mice. In old mice whose macrophages lacked EP2, 59 of those 71 stayed at youthful levels.
Many of those drifting proteins come from the liver — fitting, since the liver is one of the most macrophage-dense organs in the body and, in Andreasson's phrase, "the central organ determining the body's metabolic rate." Last week I wrote about the liver keeping score on diet. It keeps a second score here, and it may be the one your blood test is really reading when someone tells you your "age" looks good or bad.
And this is not only lifelong engineering. In a second experiment, the group gave otherwise normal 22-month-old mice — elderly, by mouse standards — an experimental drug that blocks EP2, for two months. Total neutrophil counts and the number of senescent neutrophils moved back toward youthful levels, and aged macrophages in culture regained their appetite for worn-out cells. Prevention works; so does a course of treatment begun in old age. That distinction matters, because it is the difference between a curiosity and a medicine.
The liver already knew
The mouse work would be one thing. The Stanford group then went looking in human tissue — a large database of liver cells from young, old and diseased human donors — and found the same pattern: older human livers showed more neutrophil accumulation, more senescent neutrophils, declining resident-macrophage function and elevated EP2 activity. Diseased livers were worse still. Andreasson called it the first time these changes had been seen in human cells. The switch is not a mouse artefact; human livers appear to be running the same programme, with the same accumulating arrears.
The anti-aging aisle had it half right
For a decade, the longevity field has treated senescent cells as the enemy — the "zombie cells" that leak inflammation — and built an industry around killing them with senolytic drugs. The new work re-frames the problem. Senescent cells were never the anomaly: your body produces a hundred billion short-lived neutrophils a day, and a rising share of them go senescent as you age. The disease is not that the zombies exist. It is that the crew that used to clear them has gone deaf. The fix is not carpet-bombing your own tissues; it is re-arming the crew that was there all along.
That reframing also explains a long-standing disappointment. Aspirin and other NSAIDs work by cutting PGE2 production — the upstream signal — which is why they have looked vaguely protective in big observational studies for decades, and why they have never been the anti-aging hack people hoped: they suppress the ligand crudely, hitting other prostaglandins and even the beneficial jobs PGE2 does through its other receptors. No approved drug yet blocks EP2 selectively. That specificity — the difference between turning down the whole inflammatory orchestra and muting the one receptor that deafens the cleanup crew — is now one of the most interesting drug targets in aging research, and it has a mouse result behind it that says the direction is right.
The brain is not the exception
Every theory of aging eventually meets the brain, where the usual reply is: the brain is special. It is "immune-privileged," sealed behind the blood-brain barrier, its resident immune cells — microglia — born locally and self-renewing. If aging is a body-wide immune failure, the brain should be exempt.
Two weeks after the EP2 paper went online, a Stanford team led by Julia Belk, Howard Chang and Siddhartha Jaiswal dismantled that exemption (Nature, July 2026). By using somatic mutations as natural barcodes, they traced the ancestry of microglia in human brains and found that blood-derived immune cells migrate into the brain starting in middle age and take up residence as microglia. The brain's immune population is not closed after all; it is being topped up from the bloodstream — on the same systemic clock as every other organ. Consistent with that, the EP2-deleted mice showed reduced inflammation in the hippocampus and preserved memory. Brain aging, the paper and the mouse together suggest, rides the same immune housekeeping schedule as the liver and the heart. There is no organ-specific refuge.
The people who outran the clock
Then there is the human counterexample, published in Cell Reports in August. A Japanese group led by Kosuke Hashimoto — the same group that first spotted the cells in 2019 — studied the blood of people who have done the one thing almost nobody does: reach 110. Supercentenarians, the researchers found, carry unusually high levels of a rare immune cell type, CD4 cytotoxic T lymphocytes, that kill abnormal cells, including cancer cells. The median proportion of CD4 CTLs among their blood cells rose from about 4% in people in their seventies to nineties to 9.6% among centenarians and 17.6% among those aged 110 and older. The multiplication visibly begins around age 100 — and, tellingly, these expanded clones show none of the exhaustion that cripples most aging T cells.
Read that against the standard story of immunosenescence — the immune system winding down, a little more each decade — and it is a photograph of the opposite: in the longest-lived humans, one arm of the immune system's killing force was still expanding at an age when most bodies have none left. The authors are careful, and so should we be: the numbers are small, the biology could be cause, consequence or selection — perhaps these are simply the people whose immune systems stayed this way, which is why they are still here. But put the three papers together and the silhouette is hard to miss. Mice whose cleanup crew is kept responsive stay young across eight organs. Human brains keep importing immune cells from the blood as they age. And the oldest humans on record are the ones whose killer cells never stopped multiplying.
Don't raid the pharmacy
What does this mean for a person, today? Three things, and the first two are about what not to do. Do not reach for chronic NSAIDs as an anti-aging strategy — the crude version of this switch, with real harms attached, aimed at the wrong end of the pathway. And do not chase "senolytic" supplements: nothing over the counter selectively clears senescent cells, and the new science suggests the clearing was never the scarce resource — a competent crew was.
The interesting action is downstream of the pharmacy. EP2-selective antagonists are the drug race to watch; when human trials open, that is the molecule with a mechanism, not a marketing story. In the meantime, the boring levers acquire a sharper justification: the things known to cut chronic inflammation — regular movement, decent sleep, and losing the liver fat I wrote about last week — now look plausibly like they do part of their work by keeping this exact crew responsive. And the measurement future is visible in that chart: blood proteins, many of them liver-made, that drift with age and hold steady when housekeeping works. Your grandmother's intuition — that some people simply "age better" — is becoming a blood test with a mechanism attached.
What this can't tell you
The honesty section. These are mice, first of all — magnificent, carefully engineered mice, but mice; the human data so far are observational, in tissue banks. The EP2 deletions ran from early adulthood, which is prevention; the two-month drug course in elderly mice is the more intervention-like result, and it moved neutrophils, not yet a full lifespan. One receptor is, in Andreasson's own words, "at least one big reason" — not the whole story of a process as layered as aging. And the supercentenarian result is a correlation in an extraordinary handful of people, not a prescription.
The anti-aging industry sells a picture of the body as a machine wearing out — rusting gears, thinning oil, parts to be replaced one organ at a time. The science this summer tells a different, better story. You are not a machine; you are a city, and the city's sanitation department decides the decade. When the trucks run, the streets stay clean into old age — the mice prove the crew can be kept on the job, and the 110-year-olds prove the job can be done for a very long time indeed. Nobody has made the switch into a pill yet. But for the first time in the long, scam-filled history of anti-aging medicine, the switch is not a metaphor. It is a receptor, it has a name, and the crew it silences clears a hundred billion cells a day. Fifty years of trying to slow the rust, and it turns out the fix was the pickup schedule.
Sources
- Tan, Y.J., Conley, T.E., Yao, F., García-Marqués, F.J., Akinyemi, D.E., Dinh, V.V., Wang, Q., Bermudez, A., Kim, J., Belk, J.A., Soehnlein, O., Pitteri, S.J., Andreasson, K.I. "Restored clearance of senescent neutrophils by tissue-resident macrophages limits organ aging." Science (2026). PMID 42462036 (published online 16 Jul 2026).
- Belk, J.A., Zhang, Y., Reilly, E.E., et al. "Somatic mutations reveal the ontogeny of microglia in human ageing." Nature (2026). DOI: 10.1038/s41586-026-10939-0.
- Hashimoto, K., Kojima-Ishiyama, M., Inokuchi, H., et al. "CD4 CTLs in supercentenarians: Signs of adaptive expansion in healthy aging." Cell Reports (2026). DOI: 10.1016/j.celrep.2026.117728.
- Stanford Medicine. "Breakdown of immune cells' interaction is key driver in aging, study finds." News release, 16 Jul 2026 (syndicated via ScienceDaily, 1 Sep 2026). Quotes and coverage-level figures as reported therein.